Article Versions Notes

González M, Ellahioui Y, Álvarez R, Gallego-Yerga L, Caballero E, Vicente-Blázquez A, Ramudo L, Marín Folgado M, Sanz C, Medarde M, et al. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors. Molecules. 2019; 24(23):4319. https://doi.org/10.3390/molecules24234319

González, Myriam, Younes Ellahioui, Raquel Álvarez, Laura Gallego-Yerga, Esther Caballero, Alba Vicente-Blázquez, Laura Ramudo, Miguel Marín Folgado, Cristina Sanz, Manuel Medarde, and et al. 2019. "The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors" Molecules 24, no. 23: 4319. https://doi.org/10.3390/molecules24234319

González, M., Ellahioui, Y., Álvarez, R., Gallego-Yerga, L., Caballero, E., Vicente-Blázquez, A., Ramudo, L., Marín Folgado, M., Sanz, C., Medarde, M., & Pelaéz, R. (2019). The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors. Molecules, 24(23), 4319. https://doi.org/10.3390/molecules24234319